Back to top
more

Immatics (IMTX)

(Real Time Quote from BATS)

$9.41 USD

9.41
388,204

-0.04 (-0.42%)

Updated Aug 31, 2026 02:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (160 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Company News for Nov 18, 2025

by Zacks Equity Research

Companies in The News Are: ARMK,JJSF,IMTX,TWST

Zacks Equity Research

Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Immatics (IMTX) delivered earnings and revenue surprises of +2.00% and -50.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of 0.00% and +412.62%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xilio Therapeutics (XLO) delivered earnings and revenue surprises of 0.00% and -28.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates

by Zacks Equity Research

Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +14.29% and +11.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of +15.38% and +64.26%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Geron (GERN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Geron (GERN) delivered earnings and revenue surprises of 0.00% and -10.03%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -12.24% and -25.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Krystal Biotech (KRYS) delivered earnings and revenue surprises of +137.50% and +6.89%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for August 15th

by Zacks Equity Research

IMTX, ERJ and BFIN have been added to the Zacks Rank #5 (Strong Sell) List on August 15, 2025.